This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20251112744527\/en\/<\/a><\/p>\n Owlet partners with Rhapsody to securely connect infant vital signs from Owlet\u2019s FDA-cleared, prescription pulse oximeter, BabySat\u00ae, directly into their existing electronic health record (EHR) workflows.<\/p>\n<\/div>\n \nThe integration creates a secure, standards-based pathway for Owlet\u2019s pediatric data to flow seamlessly into existing provider environments, enabling clinicians to view and record important data information as part of their standard patient records. With Rhapsody\u2019s flexible integration solution, healthcare organizations can reduce custom development, minimize errors, and ensure accurate, timely patient information is available when and where it\u2019s needed most.<\/p>\n \n\u201cOur partnership with Rhapsody is another step forward in Owlet\u2019s mission to redefine how infant data is integrated and used more effectively within the healthcare system,\u201d said Jonathan Harris, Owlet\u2019s President and CEO. \u201cWe\u2019re connecting the dots between home and hospital by delivering clinically validated infant monitoring that keeps parents and providers connected from anywhere. By integrating with the Rhapsody trusted exchange platform, we\u2019ve made sharing infant health data simple, empowering families to make informed decisions and allowing clinicians to deliver better care.\u201d<\/p>\n \nBy simplifying data connectivity between home and clinical settings, the partnership makes it easier for hospitals to scale their pediatric remote patient monitoring (RPM) programs. Clinicians can access continuous, real-time insights from patients receiving care at home, seamlessly integrated into the tools they already use.<\/p>\n \n\u201cTrue interoperability isn\u2019t just about moving data, it\u2019s about making that data meaningful in the moments that matter,\u201d said Sagnik Bhattacharya, CEO of Rhapsody. \u201cBy connecting Owlet\u2019s clinically-validated monitoring data directly into the EHR, we\u2019re giving clinicians a fuller view of their youngest patients, and helping families feel more connected to their child\u2019s care team.”<\/p>\n \nThis integration marks a key milestone in Owlet\u2019s expansion into clinical settings and reflects growing interest in connected monitoring from healthcare systems nationwide. As Owlet continues to bridge the gap between home monitoring and hospital care, the Company remains focused on empowering parents and providers with trusted, clinically validated insights. To learn more about Owlet\u2019s FDA-cleared products, including BabySat<\/a> and Dream Sock<\/a>\u00ae<\/sup><\/a>, visit www.owletcare.<\/a>com<\/a>.<\/p>\n About Owlet, Inc.<\/b><\/p>\n \nOwlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child\u2019s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children’s well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com<\/a> and follow us on LinkedIn<\/a> and Instagram<\/a> for company news and updates.<\/p>\n About Rhapsody<\/b><\/p>\n Rhapsody<\/a> is a global leader in healthcare interoperability and digital health enablement infrastructure serving over 1,900 customers. Rhapsody enables care providers, health tech builders, and public health teams to save time, reduce costs, and recognize revenue more quickly by accelerating adoption of digital health innovation through interoperability. Rhapsody API-enabled solutions are composable and flexible to meet customers where they are, deployable in a private cloud, Rhapsody cloud, or as an iPaaS.<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cReform Act\u201d). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company\u2019s expectations regarding the outcomes and benefits of Owlet\u2019s partnership with Rhapsody and the integration of infant health insights from BabySat\u00ae into electronic health record (EHR) workflows, including potential improvements in interoperability, data connectivity and clinical workflows; the scope, timing, adoption and performance of the integration; the ability of healthcare providers to scale remote patient monitoring programs and access real-time insights; the Company\u2019s product roadmap and growth prospects; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as \u201cestimate,\u201d \u201cmay,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cgoal,\u201d \u201cpotential,\u201d \u201cupcoming,\u201d \u201coutlook,\u201d \u201cguidance,\u201d the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company\u2019s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company\u2019s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company\u2019s future results and cause those results to differ materially from those expressed in or implied by the Company\u2019s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the Rhapsody-enabled integration; (ii) the regulatory pathway for Owlet\u2019s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet\u2019s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) the Company\u2019s and its partners\u2019 obligations relating to data privacy, security and interoperability (including HIPAA, HITECH and comparable laws, and evolving standards such as HL7\/FHIR and information-blocking\/interoperability requirements), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet\u2019s ability to maintain and expand, its relationship with Rhapsody and other third-party technology, cloud, manufacturing and distribution partners; (v) Owlet\u2019s competition and the Company\u2019s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (vii) Owlet\u2019s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet\u2019s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet\u2019s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company\u2019s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xii) other risks and uncertainties set forth in the Company\u2019s other releases, public statements and filings with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including those identified in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company\u2019s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company\u2019s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251112744527\/en\/<\/a><\/span><\/p>\n Owlet Media Contact: Owlet Investor Contact: Owlet Health Contact:![\"Owlet](\"https:\/\/mms.businesswire.com\/media\/20251112744527\/en\/2640965\/4\/Owlet_BabySat.jpg\")
<\/p>\n<\/p>\n
\n
<\/b>pr@owletcare.com<\/a><\/p>\n
\n
<\/b>ir@owletcare.com<\/a><\/p>\n
\n<\/b>
health@owletcare.com<\/a><\/p>\n
![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20251112744527\/en\/2640965\/3\/Owlet_BabySat.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20251112744527\/en\/2640963\/3\/Owlet_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n